



Atty Dkt No. 051501-0278726
Pat. App. Ser. No. 09/805,449

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Liu et al.

Group Art Unit: 1647

Serial No.: ~~10/805,449~~ 09/805,449

Examiner: Landsman R.

Filed: March 13, 2001

Title:
METHODS OF MODULATING CELL
MIGRATION USING GALECTIN-3

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing the enclosed cited references in this statement.

Certificate of Mailing Under 37 C.F.R. §1.8
I hereby certify that this correspondence along with any
paper referred to as being attached is being Mailed to
Addressee by service of the United States Postal
Service addressed to Commissioner for Patents, P.O.
Box, 1450, Alexandria, VA 22313-1450

By: 
Sachiko Y. Snedden

Date: July 20, 2004

07/26/2004 MBELETE1 00000020 502212 09805449

02 FC:1806 180.00 DA

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be constructed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.

Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.


A fee of \$180 is incurred for filing this Statement. The Commissioner is hereby authorized to charge that amount and any other fee that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment, to Deposit Account No. 50-2212, Order No. 051501-0278726.

Respectfully submitted,

Pillsbury Winthrop LLP

Date: July 20, 2004

By


Robert M. Bedgood, Ph.D.
Reg. No. 43,488

11682 El Camino Real
Suite 200
San Diego, CA 92130-2092
(619) 234-5000

Tel. No. (858) 509-4065
Fax No. (858) 509-4010



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

C-M#

Client Ref.

051501-0278726

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Inventor(s): Liu et al.

Appln. No.: 10/805,449

Filing Date: March 13, 2001

Date: July 20, 2004

Page 1 of 1

Examiner: Landsman R.

Group Art Unit: 1647

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's Initials*			English Abstract		Translation Readily Available	
			Enclosed	No	Enclosed	No
	AR	Nangia-Makker et al.; Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis; American Journal of Pathology, vol. 156, no. 3; March 2000; pp. 899-909				
	BR	Yang et al.; Expression of galectin-3 modulates T-cell growth and apoptosis; Proc. Natl. Acad. Sci. USA, vol. 93; June 1996; pp. 6737-6742				
	CR	Frigeri et al.; ϵ BP, a β -Galactoside-Binding Animal Lectin, Recognizes IgE Receptor (Fc ϵ RI) and Activates Mast Cells; Biochemistry, vol. 32; no. 30; 1993; pp. 7644-7649				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.